HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $90 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a $90 price target.
August 09, 2023 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arrowhead Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $90.
The reiteration of a 'Buy' rating and a maintained price target of $90 by HC Wainwright & Co. indicates a positive outlook for Arrowhead Pharma. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100